Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol 2018;15:366–81.
Google Scholar
Yang S, Hu H, Kung H, Zou R, Dai Y, Hu Y, et al. Organoids: the current status and biomedical applications. MedComm. 2023;4:e274.
Google Scholar
Veninga V, Voest EE. Tumor organoids: opportunities and challenges to guide precision medicine. Cancer Cell. 2021;39:1190–201.
Google Scholar
de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374–403.
Google Scholar
Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, et al. Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell. 2018;174:1586–98.e1512.
Google Scholar
Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer. 2018;18:335.
Google Scholar
Yuki K, Cheng N, Nakano M, Kuo CJ. Organoid Models of Tumor Immunology. Trends Immunol 2020;41:652–64.
Google Scholar
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Google Scholar
Yang H, Wang Y, Wang P, Zhang N, Wang P. Tumor organoids for cancer research and personalized medicine. Cancer Biol Med. 2021;19:319–32.
Google Scholar
Xu H, Jiao D, Liu A, Wu K. Tumor organoids: applications in cancer modeling and potentials in precision medicine. J Hematol Oncol. 2022;15:58.
Google Scholar
Fiorini E, Veghini L, Corbo V. Modeling cell communication in cancer with organoids: making the complex simple. Front Cell Dev Biol. 2020;8:166.
Google Scholar
Zhao Z, Chen X, Dowbaj AM, Sljukic A, Bratlie K, Lin L, et al. Organoids. Nat Rev Methods Prim. 2022;2:94.
Google Scholar
Xu H, Lyu X, Yi M, Zhao W, Song Y, Wu K. Organoid technology and applications in cancer research. J Hematol Oncol. 2018;11:116.
Google Scholar
Schnalzger TE, de Groot MH, Zhang C, Mosa MH, Michels BE, Röder J, et al. 3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids. Embo J. 2019;38:e100928.
Google Scholar
Tsai KK, Huang SS, Northey JJ, Liao WY, Hsu CC, Cheng LH, et al. Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity. Nat Cancer. 2022;3:734–52.
Google Scholar
Wang W, Yuan T, Ma L, Zhu Y, Bao J, Zhao X, et al. Hepatobiliary Tumor Organoids Reveal HLA Class I Neoantigen Landscape and Antitumoral Activity of Neoantigen Peptide Enhanced with Immune Checkpoint Inhibitors. Adv Sci. 2022;9:e2105810.
Google Scholar
Carneiro BA, Pamarthy S, Shah AN, Sagar V, Unno K, Han H, et al. Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. Clin Cancer Res. 2018;24:2732–9.
Google Scholar
Shi R, Radulovich N, Ng C, Liu N, Notsuda H, Cabanero M, et al. Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer. Clin Cancer Res. 2020;26:1162–74.
Google Scholar
Driehuis E, Clevers H. CRISPR/Cas 9 genome editing and its applications in organoids. Am J Physiol Gastrointest Liver Physiol. 2017;312:G257–g265.
Google Scholar
Yuan J, Li X, Yu S. Cancer organoid co-culture model system: Novel approach to guide precision medicine. Front Immunol. 2022;13:1061388.
Google Scholar
Weng G, Tao J, Liu Y, Qiu J, Su D, Wang R, et al. Organoid: Bridging the gap between basic research and clinical practice. Cancer Lett. 2023;572:216353.
Google Scholar
Gun SY, Lee SWL, Sieow JL, Wong SC. Targeting immune cells for cancer therapy. Redox Biol. 2019;25:101174.
Google Scholar
Ganeshan K, Chawla A. Metabolic regulation of immune responses. Annu Rev Immunol. 2014;32:609–34.
Google Scholar
Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6:263.
Google Scholar
Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267–84.
Google Scholar
Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, et al. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126–33.
Google Scholar
Muenst S, Läubli H, Soysal SD, Zippelius A, Tzankov A, Hoeller S. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med. 2016;279:541–62.
Google Scholar
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.
Google Scholar
Wang J, Loeuillard E, Gores GJ, Ilyas SI. Cholangiocarcinoma: what are the most valuable therapeutic targets – cancer-associated fibroblasts, immune cells, or beyond T cells? Expert Opin Ther Targets. 2021;25:835–45.
Google Scholar
Li Y, Wang J, Song SR, Lv SQ, Qin JH, Yu SC. Models for evaluating glioblastoma invasion along white matter tracts. Trends Biotechnol. 2024;42:293–309.
Google Scholar
Strating E, Verhagen MP, Wensink E, Dünnebach E, Wijler L, Aranguren I, et al. Co-cultures of colon cancer cells and cancer-associated fibroblasts recapitulate the aggressive features of mesenchymal-like colon cancer. Front Immunol. 2023;14:1053920.
Google Scholar
Sheng N, Shindo K, Ohuchida K, Shinkawa T, Zhang B, Feng H, et al. TAK1 Promotes an Immunosuppressive Tumor Microenvironment through Cancer-Associated Fibroblast Phenotypic Conversion in Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2024;30:5138–53.
Google Scholar
Song H, Lu T, Han D, Zhang J, Gan L, Xu C, et al. YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer. Cancer Res. 2024;84:3728–42.
Google Scholar
Harter MF, Recaldin T, Gerard R, Avignon B, Bollen Y, Esposito C, et al. Analysis of off-tumour toxicities of T-cell-engaging bispecific antibodies via donor-matched intestinal organoids and tumouroids. Nat Biomed Eng. 2023;8:345–60.
Google Scholar
Augustine TN. Analysis of Immune-Tumor Cell Interactions Using a 3D Co-culture Model. Methods Mol Biol. 2020;2184:103–10.
Google Scholar
Verma NK, Wong BHS, Poh ZS, Udayakumar A, Verma R, Goh RKJ, et al. Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint. EBioMedicine. 2022;83:104216.
Google Scholar
Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651–68.
Google Scholar
Zhou G, Lieshout R, van Tienderen GS, de Ruiter V, van Royen ME, Boor PPC, et al. Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells. Br J Cancer. 2022;127:649–60.
Google Scholar
Holokai L, Chakrabarti J, Lundy J, Croagh D, Adhikary P, Richards SS, et al. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Cancers. 2020;12:3816.
Google Scholar
Wang X, Fang Y, Liang W, Wong CC, Qin H, Gao Y, et al. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell. 2024;42:1729–46.e8.
Google Scholar
Chakrabarti J, Koh V, So JBY, Yong WP, Zavros Y. A Preclinical Human-Derived Autologous Gastric Cancer Organoid/Immune Cell Co-Culture Model to Predict the Efficacy of Targeted Therapies. J Vis Exp. 2021;173.
Küçükköse E, Heesters BA, Villaudy J, Verheem A, Cercel M, van Hal S, et al. Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice. J Immunother Cancer. 2022;10:e005345.
Google Scholar
Sahin U. Studying Tumor-ReacTive T Cells: A Personalized Organoid Model. Cell Stem Cell. 2018;23:318–9.
Google Scholar
Hu B, Wang R, Wu D, Long R, Fan J, Hu Z, et al. A Promising New Model: Establishment of Patient‐Derived Organoid Models Covering HPV‐Related Cervical Pre‐Cancerous Lesions and Their Cancers. Adv Sci. 2024;11:e2302340.
Google Scholar
Liu Y, Lankadasari M, Rosiene J, Johnson KE, Zhou J, Bapat S, et al. Modeling lung adenocarcinoma metastases using patient-derived organoids. Cell Rep. Med. 2024;5:101777.
Google Scholar
Liu C, Li K, Sui X, Zhao T, Zhang T, Chen Z, et al. Patient‐Derived Tumor Organoids Combined with Function‐Associated ScRNA‐Seq for Dissecting the Local Immune Response of Lung Cancer. Adv Sci. 2024;11:e2400185.
Google Scholar
Li K, Liu C, Li C, Zhang T, Zhao T, Zhang D et al. An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer. bioRxiv. Version 2 (2024). https://doi.org/10.1101/2024.06.04.597327.
Feodoroff M, Hamdan F, Antignani G, Feola S, Fusciello M, Russo S, et al. Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses. OncoImmunology. 2024;13:2407532.
Google Scholar
Shan H, Chen M, Zhao S, Wei X, Zheng M, Li Y, et al. Acoustic virtual 3D scaffold for direct-interacting tumor organoid-immune cell coculture systems. Sci Adv. 2024;10:eadr4831.
Google Scholar
Wang X, Dai Z, Lin X, Zou X, Wang R, Tasiheng Y, et al. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid application. Cancer Lett. 2024;588:216741.
Google Scholar
Jacob F, Ming GL, Song H. Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing. Nat Protoc. 2020;15:4000–33.
Google Scholar
Yu L, Li Z, Mei H, Li W, Chen D, Liu L, et al. Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro. Clin Transl Immunol. 2021;10:e1248.
Google Scholar
Wehrli M, Guinn S, Birocchi F, Kuo A, Sun Y, Larson RC, et al. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma. Clin Cancer Res. 2024;30:1859–77.
Google Scholar
Maulana TI, Teufel C, Cipriano M, Roosz J, Lazarevski L, van den Hil FE, et al. Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells. Cell Stem Cell. 2024;31:989–1002.e1009.
Google Scholar
Logun M, Wang X, Sun Y, Bagley SJ, Li N, Desai A, et al. Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy. Cell Stem Cell. 2025;32:181–90.e4.
Google Scholar
Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, et al. The CD39(+) HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8(+) T cells exhibit potent anti-HCC activity. Mol Ther. 2021;29:1794–807.
Google Scholar
Martins P, D’Souza RCJ, Skarne N, Lekieffre L, Horsefield S, Ranjankumar M, et al. EphA3 CAR T cells are effective against glioblastoma in preclinical models. J Immunother Cancer. 2024;12:e009403.
Google Scholar
Qayoom H, Sofi S, Mir MA. Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis. Immunol Res. 2023;71:588–99.
Google Scholar
Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93–103.
Google Scholar
Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F, et al. Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges. Cancers. 2022;14:4160.
Google Scholar
Shin JH, Jeong J, Maher SE, Lee HW, Lim J, Bothwell ALM. Colon cancer cells acquire immune regulatory molecules from tumor-infiltrating lymphocytes by trogocytosis. Proc Natl Acad Sci. 2021;118:e2110241118.
Google Scholar
Ou L, Liu S, Wang H, Guo Y, Guan L, Shen L, et al. Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. eBioMedicine. 2023;92:104614.
Google Scholar
Huang H, Pan Y, Huang J, Zhang C, Liao Y, Du Q, et al. Patient-derived organoids as personalized avatars and a potential immunotherapy model in cervical cancer. iScience. 2023;26:108198.
Google Scholar
Li Z, Ma L, Gao Z, Wang X, Che X, Zhang P, et al. Identification and validation of tumor-specific T cell receptors from tumor infiltrating lymphocytes using tumor organoid co-cultures. Cancer Immunol Immunother. 2024;73:164.
Google Scholar
Wang F, Zhang G, Xu T, Ma J, Wang J, Liu S, et al. High and selective cytotoxicity of ex vivo expanded allogeneic human natural killer cells from peripheral blood against bladder cancer: implications for natural killer cell instillation after transurethral resection of bladder tumor. J Exp Clin Cancer Res. 2024;43:24.
Google Scholar
Zhou Y, Cheng L, Liu L, Li X. NK cells are never alone: crosstalk and communication in tumour microenvironments. Mol Cancer 2023;22:34.
Google Scholar
Chan IS, Ewald AJ. Organoid Co-culture Methods to Capture Cancer Cell-Natural Killer Cell Interactions. Methods Mol Biol 2022;2463:235–50.
Google Scholar
Chan IS, Knútsdóttir H, Ramakrishnan G, Padmanaban V, Warrier M, Ramirez JC, et al. Cancer cells educate natural killer cells to a metastasis-promoting cell state. J Cell Biol 2020;219:e202001134.
Google Scholar
Marcon F, Zuo J, Pearce H, Nicol S, Margielewska-Davies S, Farhat M, et al. NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype. Oncoimmunology. 2020;9:1845424.
Google Scholar
Park MD, Silvin A, Ginhoux F, Merad M. Macrophages in health and disease. Cell. 2022;185:4259–79.
Google Scholar
Pan Y, Yu Y, Wang X, Zhang T. Tumor-Associated Macrophages in Tumor Immunity. Front Immunol. 2020;11:583084.
Google Scholar
Kim J, Bae JS. Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment. Mediators Inflamm. 2016;2016:6058147.
Google Scholar
Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21:799–820.
Google Scholar
Linde N, Gutschalk CM, Hoffmann C, Yilmaz D, Mueller MM. Integrating macrophages into organotypic co-cultures: a 3D in vitro model to study tumor-associated macrophages. PLoS One. 2012;7:e40058.
Google Scholar
Zou Z, Lin Z, Wu C, Tan J, Zhang J, Peng Y, et al. Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients. Adv Sci. 2023;10:e2302640.
Google Scholar
Fang H, Huang Y, Luo Y, Tang J, Yu M, Zhang Y, et al. SIRT1 induces the accumulation of TAMs at colorectal cancer tumor sites via the CXCR4/CXCL12 axis. Cell Immunol. 2022;371:104458.
Google Scholar
Jiang S, Deng T, Cheng H, Liu W, Shi D, Yuan J, et al. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance. J Exp Clin Cancer Res. 2023;42:199.
Google Scholar
Liu K. Dendritic cells. Encycl Cell Biol. 2016;3:741–9. https://doi.org/10.1016/B978-0-12-394447-4.30111-0.
Google Scholar
Peng X, He Y, Huang J, Tao Y, Liu S. Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy. Front Immunol. 2021;12:613492.
Google Scholar
Zhang B, Ohuchida K, Tsutsumi C, Shimada Y, Mochida Y, Oyama K, et al. Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2024;43:271.
Google Scholar
Subtil B, Iyer KK, Poel D, Bakkerus L, Gorris MAJ, Escalona JC, et al. Dendritic cell phenotype and function in a 3D co-culture model of patient-derived metastatic colorectal cancer organoids. Front Immunol. 2023;14:1105244.
Google Scholar
Subtil B, van der Hoorn IAE, Cuenca‐Escalona J, Becker AMD, Alvarez‐Begue M, Iyer KK, et al. cDC2 plasticity and acquisition of a DC3‐like phenotype mediated by IL‐6 and PGE2 in a patient‐derived colorectal cancer organoids model. Eur J Immunol 2024;54:e2350891.
Google Scholar
Lück AS, Pu J, Melhem A, Schneider M, Sharma A, Schmidt-Wolf IGH, et al. Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma. Sci Rep. 2025;15:734.
Google Scholar
Hou Y, Kong F, Tang Z, Zhang R, Li D, Ge J, et al. Nitroxide radical conjugated ovalbumin theranostic nanosystem for enhanced dendritic cell-based immunotherapy and T1 magnetic resonance imaging. J Controlled Release. 2024;373:547–63.
Google Scholar
Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, et al. Organoid Modeling of the Tumor Immune Microenvironment. Cell. 2018;175:1972–88.e16.
Google Scholar
Zhang SW, Wang H, Ding XH, Xiao YL, Shao ZM, You C, et al. Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: Beyond tumor antigens. Fundam Res. 2023;3:1005–24.
Google Scholar
Ye W, Luo C, Li C, Huang J, Liu F. Organoids to study immune functions, immunological diseases and immunotherapy. Cancer Lett. 2020;477:31–40.
Google Scholar
Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–72.
Google Scholar
Ko KP, Huang Y, Zhang S, Zou G, Kim B, Zhang J, et al. Key Genetic Determinants Driving Esophageal Squamous Cell Carcinoma Initiation and Immune Evasion. Gastroenterology. 2023;165:613–28.e620.
Google Scholar
Norkin M, Ordóñez-Morán P, Huelsken J. High-content, targeted RNA-seq screening in organoids for drug discovery in colorectal cancer. Cell Rep. 2021;35:109026.
Google Scholar
van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933–45.
Google Scholar
LeSavage BL, Suhar RA, Broguiere N, Lutolf MP, Heilshorn SC. Next-generation cancer organoids. Nat Mater. 2022;21:143–59.
Google Scholar
Aisenbrey EA, Murphy WL. Synthetic alternatives to Matrigel. Nat Rev Mater. 2020;5:539–51.
Google Scholar
Hughes CS, Postovit LM, Lajoie GA. Matrigel: a complex protein mixture required for optimal growth of cell culture. Proteomics. 2010;10:1886–90.
Google Scholar
Lu P, Weaver VM, Werb Z. The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol. 2012;196:395–406.
Google Scholar
Chrisnandy A, Blondel D, Rezakhani S, Broguiere N, Lutolf MP. Synthetic dynamic hydrogels promote degradation-independent in vitro organogenesis. Nat Mater. 2021;21:479–87.
Google Scholar
Gan Z, Qin X, Liu H, Liu J, Qin J. Recent advances in defined hydrogels in organoid research. Bioact Mater. 2023;28:386–401.
Google Scholar
Yin S, Xi R, Wu A, Wang S, Li Y, Wang C, et al. Patient-derived tumor-like cell clusters for drug testing in cancer therapy. Sci Transl Med 2020;12:eaaz1723.
Google Scholar
Ji L, Fu G, Huang M, Kao X, Zhu J, Dai Z, et al. scRNA-seq of colorectal cancer shows regional immune atlas with the function of CD20(+) B cells. Cancer Lett. 2024;584:216664.
Google Scholar
Zhou Z, Cong L, Cong X. Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank. Front Oncol. 2021;11:762184.
Google Scholar
Dsouza VL, Kuthethur R, Kabekkodu SP, Chakrabarty S. Organ-on-Chip platforms to study tumor evolution and chemosensitivity. Biochimica et Biophysica Acta Rev Cancer 2022;1877:188717.
Google Scholar
Kronemberger GS, Miranda G, Tavares RSN, Montenegro B, Kopke ÚA, Baptista LS. Recapitulating Tumorigenesis in vitro: Opportunities and Challenges of 3D Bioprinting. Front Bioeng Biotechnol. 2021;9:682498.
Google Scholar
Kulkarni A, Ferreira N, Scodellaro R, Choezom D, Alves F. A Curated Cell Life Imaging Dataset of Immune-enriched Pancreatic Cancer Organoids with Pre-trained AI Models. Sci Data. 2024;11:820.
Google Scholar
Wang H, Li X, You X, Zhao G. Harnessing the power of artificial intelligence for human living organoid research. Bioact Mater. 2024;42:140–64.
Google Scholar
Bai L, Wu Y, Li G, Zhang W, Zhang H, Su J. AI-enabled organoids: Construction, analysis, and application. Bioact Mater. 2024;31:525–48.
Google Scholar
Moreno Ayala MA, Campbell TF, Zhang C, Dahan N, Bockman A, Prakash V, et al. CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity. Immunity. 2023;56:1613–30.e5.
Google Scholar
Bouffi C, Wikenheiser-Brokamp KA, Chaturvedi P, Sundaram N, Goddard GR, Wunderlich M, et al. In vivo development of immune tissue in human intestinal organoids transplanted into humanized mice. Nat Biotechnol. 2023;41:824–31.
Google Scholar
link